Story

Philip Morris Options Market Prices in 4.9% Post-Earnings Move

ENTHMSVIIDZHZH-TWJAKOHI
Jul 15, 20261 min read
Philip Morris Options Market Prices in 4.9% Post-Earnings Move

Summary

Options traders are anticipating a nearly 5% swing in Philip Morris's stock price following its July 22 earnings release. Historical data shows the stock has often moved more than the implied volatility suggests.

Text size
Background

Options markets are pricing in a potential 4.9% price swing for Philip Morris International Inc. (PM) shares following the company's upcoming earnings report on July 22, according to data compiled by Bloomberg.

The tobacco giant is scheduled to release its financial results before the market opens. The implied move is derived from the pricing of options contracts and reflects investor expectations for volatility surrounding the announcement, not the direction of the price change.

Historical Performance vs. Expectations

An analysis of the company's past earnings announcements shows that the stock's actual price movement has frequently been more volatile than options pricing suggested. In five of the past eight earnings reports, Philip Morris shares moved more than the implied amount.

While the two most recent reports in April and February saw the stock's reaction fall short of expectations, there have been several instances of significant divergence:

Sample IUX Markets – In-articleAd
  • February 2025: The stock surged 12.1%, far exceeding the 3.7% implied move.
  • October 2024: Shares climbed 9.4% against an expected 3.6% change.
  • July 2025: The stock fell 8.6%, nearly double the 4.8% move priced in by options.

Context for Investors

Implied volatility serves as a key barometer of market uncertainty ahead of a scheduled catalyst like an earnings release. A higher-than-expected figure can indicate that traders are anticipating a significant surprise in revenue, profit, or forward-looking guidance.

Conversely, a stock move that is smaller than implied can occur if the company's results are largely in line with Wall Street's consensus estimates, leading to a more muted market reaction. For investors, this data provides a benchmark for the level of risk and potential price fluctuation being priced into the market ahead of the report.

Read next

More on Stocks
Shenzhen-Listed Jingxin Pharmaceutical Refiles for Hong Kong IPO

Stocks

Shenzhen-Listed Jingxin Pharmaceutical Refiles for Hong Kong IPO

Sep 20, 2026

Zhejiang Jingxin Pharmaceutical Co., Ltd. (002020.SZ) has resubmitted its application for a main board listing on the Hong Kong Stock Exchange, aiming to secure a dual listing to access international capital. The company specializes in drugs for central nervous system and cardiovascular diseases.

Back to latest news

LATEST